Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Narcolepsy with cataplexy and comorbid immunopathological diseases.
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D(3) in Experimental Autoimmune Encephalomyelitis.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Ceramide Synthase 6 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis.
"Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection.
Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects.
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Clinical overview of the seizure risk of dalfampridine.

Pages